Dexamethasone/netilmicin - SIFI
Alternative Names: Dexamethasone/netilmicin; Netildex; Netilmicin/dexamethasoneLatest Information Update: 07 Dec 2022
At a glance
- Originator SIFI
- Developer Knight Therapeutics; SIFI
- Class Aminocyclitols; Aminoglycosides; Anti-infectives; Anti-inflammatories; Antibacterials; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids
- Mechanism of Action Arachidonic acid inhibitors; Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular inflammation
Most Recent Events
- 07 Dec 2022 No development reported - Phase-III for Ocular inflammation in Italy (Ophthalmic) prior to December 2022
- 23 Oct 2019 Registered for Ocular inflammation in Canada (Ophthalmic, Drops)
- 01 Dec 2018 SIFI completes a phase-III clinical trial in Ocular inflammation in Italy (Ophthalmic, Gel) (EudraCT2016-002138-63) (NCT02973880)